BOSTON--(BUSINESS WIRE)--HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625), developing its cell-based bioartificial liver system, HepaMate™, as a potentially lifesaving treatment for liver failure patients, announced today that it plans for a new pivotal Phase III clinical trial in the United States.
